Security
Bone Biologics Corp Common Stock · BBLG
BBLGOTCCommon stockHistorical · closed Oct 13, 2021CIK 1419554Updated Oct 27, 2026
Name history
Bone Biologics, Corp. · through Nov 2, 2015AFH ACQUISITION X, INC. · through Sep 15, 2014
Current security for this SEC filerBBLG · NASDAQ
BBLG price & chart
Historical security
This listing closed Oct 13, 2021. Live provider charts are shown only for current listings.
Current security: BBLG
About the company
We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (“DBM”) is an osteopromotive recombinant protein that provides target specific control over bone regeneration. The NELL-1 technology platform has been licensed exclusively for worldwide applications to us through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the U.S. Food and Drug Administration (“FDA”) that NELL-1/DBM will be classified as a device/drug combination product that will require an FDA-approved pre-market approval (“PMA”) application before it can be commercialized in the United States.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
25-NSE - filed by Nasdaq Stock Market LLC regarding Bone Biologics Corp
Submission of Matters to a Vote of Security Holders
Items 5.07
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
DEF 14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 6,350,799Source | 4,065,818Source | 4,436,668Source | 7,002,216Source | 3,193,464Source | 4,979,305Source | 3,162,060Source | 3,839,574Source | 5,796,135Source | 3,861,369Source | 3,737,763Source | 8,495,237Source |
| Current assets: | ||||||||||||
| Assets, CurrentUSD | 6,350,799Source | 4,065,818Source | 4,436,668Source | 7,002,216Source | 3,193,464Source | 4,979,305Source | 3,162,060Source | 3,839,574Source | 5,796,135Source | 3,861,369Source | 3,737,763Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 334,282Source | 273,402Source | 512,018Source | 406,142Source | 284,507Source | 309,386Source | 251,158Source | 164,626Source | 418,587Source | 377,712Source | 831,402Source | 2,547,929Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,795Source | 2,096Source | 1,810Source | 1,685Source | 1,315Source | 1,795Source | 3,270Source | 1,016Source | 1,795Source | 2,953Source | 534Source | 15,300Source |
| Additional Paid in CapitalUSD | 93,460,448Source | 87,289,983Source | 93,592,899Source | 93,373,378Source | 85,466,303Source | 93,564,481Source | 88,946,102Source | 85,448,860Source | 93,506,122Source | 88,502,082Source | 83,814,785Source | 77,892,235Source |
| Retained Earnings (Accumulated Deficit)USD | -87,445,726Source | -83,499,663Source | -89,670,059Source | -86,778,989Source | -82,558,661Source | -88,896,357Source | -86,038,470Source | -81,774,928Source | -88,130,369Source | -85,021,378Source | -80,908,958Source | -71,960,227Source |
| Stockholders' Equity Attributable to ParentUSD | 6,016,517Source | 3,792,416Source | 3,924,650Source | 6,596,074Source | 2,908,957Source | 4,669,919Source | 2,910,902Source | 3,674,948Source | 5,377,548Source | 3,483,657Source | 2,906,361Source | 5,947,308Source |
| Liabilities and EquityUSD | 6,350,799Source | 4,065,818Source | 4,436,668Source | 7,002,216Source | 3,193,464Source | 4,979,305Source | 3,162,060Source | 3,839,574Source | 5,796,135Source | 3,861,369Source | 3,737,763Source | 8,495,237Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 334,282Source | 273,402Source | 512,018Source | 406,142Source | 284,507Source | 309,386Source | 251,158Source | 164,626Source | 418,587Source | 377,712Source | 831,402Source | 2,547,929Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -800,000Source | — | -3,100,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 23,505Source | 50,605Source | 256,358Source | 188,819Source | 152,599Source | 266,633Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -804,282Source | -926,125Source | -2,691,150Source | -4,124,935Source | -9,555,904Source | -3,566,913Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 347,549Source | 4,700,341Source | 4,423,497Source | 5,044,161Source | 4,429,860Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -804,282Source | -578,576Source | 2,009,191Source | 298,562Source | -4,511,743Source | 862,947Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 527,466Source | 521,274Source | 499,359Source | 556,467Source | 663,457Source | 614,910Source | 2,174,751Source | 2,088,776Source | 2,520,479Source | 2,085,875Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -666,737Source | -941,002Source | -773,702Source | -740,519Source | -765,988Source | -1,017,092Source | -3,108,991Source | -4,112,420Source | -8,948,731Source | -1,484,620Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -666,737Source | -4,153,506Source | — | — | — | — | -3,108,991Source | -7,324,924Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 48,537Source | 10,019Source | 34,404Source | 7,556Source | 39,066Source | 21,394Source | 125,951Source | 106,741Source | 479,572Source | 2,180,553Source |
| Operating ExpensesUSD | — | — | 715,274Source | 951,021Source | 808,106Source | 748,075Source | 805,054Source | 1,038,486Source | 3,234,942Source | 4,219,161Source | 9,428,303Source | 3,665,173Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 4,352,792Source | 1,504,113Source | 5,044,161Source | 4,429,860Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -715,274Source | -951,021Source | -808,106Source | -748,075Source | -805,054Source | -1,038,486Source | -3,234,942Source | -4,219,161Source | -9,428,303Source | -3,665,173Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -666,737Source | -941,002Source | -773,702Source | -740,519Source | -765,988Source | -1,017,092Source | -3,108,991Source | -4,112,420Source | -8,948,731Source | -1,484,620Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.37Source | -14.21Source | -0.43Source | -1.33Source | -0.43Source | -1.92Source | -2.65Source | -4.83Source | -34.01Source | -0.13Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.37Source | -14.21Source | -0.43Source | -1.33Source | -0.43Source | -1.92Source | -2.65Source | -4.83Source | -34.01Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,795,097Source | 292,321Source | 1,796,755Source | 557,787Source | 1,795,260Source | 530,618Source | 1,174,869Source | 1,517,235Source | 263,137Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,795,097Source | 292,321Source | 1,796,755Source | 557,787Source | 1,795,260Source | 530,618Source | 1,174,869Source | 1,517,235Source | 263,137Source | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 527,466Source | 521,274Source | 499,359Source | 556,467Source | 663,457Source | 614,910Source | 2,174,751Source | 2,088,776Source | 2,520,479Source | 2,085,875Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 1,868Source | — |
| Interest Income, OtherUSD | — | — | 47,325Source | 19,993Source | 34,512Source | 6,654Source | 38,801Source | 20,039Source | 121,984Source | 55,660Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -666,737Source | -4,153,506Source | — | — | — | — | -3,108,991Source | -7,324,924Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 48,537Source | 10,019Source | 34,404Source | 7,556Source | 39,066Source | 21,394Source | 125,951Source | 106,741Source | 479,572Source | 2,180,553Source |
| Operating ExpensesUSD | — | — | 715,274Source | 951,021Source | 808,106Source | 748,075Source | 805,054Source | 1,038,486Source | 3,234,942Source | 4,219,161Source | 9,428,303Source | 3,665,173Source |
| Other ExpensesUSD | — | — | — | — | — | — | 445,768Source | 366,304Source | 983,054Source | — | — | — |
| Other IncomeUSD | — | — | — | — | — | — | 38,801Source | 20,039Source | 125,951Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 187,808Source | 429,747Source | 308,747Source | 191,608Source | 141,597Source | 423,576Source | 1,060,191Source | 2,130,385Source | 6,907,824Source | 1,579,298Source |
Offerings
Registration 333-297550
Registration 333-288282
- Gross proceeds
- 4999543.75
- Net proceeds
- 4649543.75
- Deal price
- 4.0
- Shares
- 1249886
- Offering price
- $4.00
- Ticker
- BBLG
Filing attachments
ex99-1.htm · 8-K · 2026-07-23
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027 BURLINGTON, Mass., July 23, 2026 --(GLOBE NEWSWIRE)--Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine f…
Read attachment ↗ex107.htm · S-3 · 2026-07-17
Calculation of Filing Fee Tables S-3 Bone Biologics Corp ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering P…
Read attachment ↗ex4-1.htm · 8-K · 2026-07-09
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex4-2.htm · 8-K · 2026-07-09
EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex4-3.htm · 8-K · 2026-07-09
EX-4.3 4 ex4-3.htm EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex4-4.htm · 8-K · 2026-07-09
EX-4.4 5 ex4-4.htm EX-4.4 Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗